Dr. Joan Schiller is widely published and internationally recognized for her work in lung cancer clinical research. She is the deputy director of Simmons Comprehensive Cancer Center, holds the Andrea L. Simmons Distinguished Chair in Cancer Research, and is division chief of Hematology/Oncology at the University of Texas-Southwestern Medical Center in Dallas, which ranks among the top academic medical centers in the world. Dr. Schiller has served as an editor for the Journal of Clinical Oncology; a board member for the International Association for the Study of Lung Cancer, and the principal investigator on many national clinical trials for lung cancer. She also served as chairperson of the Thoracic Oncology Committee of the Eastern Co-operative Oncology Group for many years until stepping down from that position in 2012.
Dr. Schiller graduated from the University of Illinois Medical School and completed her internship and residency in internal medicine at Northwestern Memorial Hospital in Chicago. She then completed a clinical fellowship in the Department of Human Oncology at the University of Wisconsin Comprehensive Cancer Center where she became the Melanie Heald Professor in the Department of Medicine, Section of Medical Oncology, and subsequently served as head of the Lung Cancer Program at the University of Wisconsin Comprehensive Cancer Center.
Dr. Schiller’s research has generated well over 200 publications that she has authored or co-authored, including articles, abstracts, book chapters, books, reviews and invited manuscripts.
Dr. Schiller is also the founder and President of Free to Breathe, a national advocacy organization aimed at raising awareness and funding for lung cancer. Free to Breathe has awarded over $4 million dollars in research funds to close to 50 investigators since 2005.
Professor of Medicine Chief, Division of Oncology Stanford University
George W. Sledge Jr., MD, is Professor and Chief of Medical Oncology at Stanford University Medical Center, as of January 2013. Dr. George Sledge was most recently co-director of the breast cancer program at the Indiana University Cancer Center, where he is was a Professor of Medicine and Pathology at the Indiana University Simon Cancer Center. He specializes in the study and treatment of breast cancer and directed the first large, nationwide study on the use of paclitaxel to treat advanced breast cancer. His recent research focuses on novel biologic treatments for breast cancer. He has published over 280 articles in medical journals about breast cancer and chaired several nationwide clinical trials involving new breast cancer treatments. His work spans both laboratory and clinic.
Dr Sledge serves as Editor-in-Chief of the journal Clinical Breast Cancer, and is Past President of the American Society of Clinical Oncology. He served as chairman of the Breast Committee of the Eastern Cooperative Oncology Group from 2002 – 2009, where he played an important role in the development of several nationwide clinical trials. He has also served as chair of ASCO’s Education Committee, as a member of the Department of Defense Breast Cancer Research Program’s Integration Panel, as a member of the Food and Drug Administration’s Oncology Drug Advisory Committee (ODAC), and currently as a member of the External Advisory Committee for The Cancer Genome Atlas (TCGA) project.
Dr. Sledge was awarded the Hope Funds for Cancer Research 2013 Award of ‘Excellence for Medicine’. Dr. Sledge was also the recipient of the 2006 Komen Foundation Brinker Award for Scientific Distinction, the 2007 Breast Cancer Research Foundation’s Jill Rose Award and was the 2010 recipient of the William L. McGuire Award from the San Antonio Breast Cancer Symposium.
Professor Johann de Bono is a Professor in Experimental Cancer Medicine at The Institute of Cancer Research and Royal Marsden. He is the Director of The Drug Development Unit, overseeing the conduct of Phase I trials, with a particular interest in innovative trial designs, circulating biomarkers and prostate cancer. He also leads the Prostate Cancer Targeted Therapy Clinical Trials Team and the Cancer Biomarkers laboratory team.
He graduated from the University of Glasgow medical school in 1989, graduating as a Member of the Royal College of Physicians (MRCP) in 1992. He was awarded a four-year Cancer Research Campaign Clinical Fellowship, which allowed him to pursue a PhD between 1993 and 1997. He trained in medical oncology, and was awarded an MSc (Cancer Sciences) from Glasgow University. The Royal College of Physicians and Surgeons of Glasgow then awarded him a travelling scholarship that allowed him to pursue further research on the challenges of clinical trial design at the SWOG statistical headquarters at the Fred Hutchinson Cancer Centre in Seattle, USA in 1999. Between 2000 and 2003 he then pursued further research developing novel anti-cancer drugs at the Institute for Drug Development within the University of Texas Health Science Centre at San Antonio.
In 2003, he was elected a Fellow of the Royal College of Physicians, and in 2009, he was elected as a Member of the Malta Order of Merit. Professor de Bono received the prestigious ESMO Award in 2012 and was part of the ICR/RMH team awarded the AACR Team Science Award. He also received an award from the Royal Society of Chemistry for his team’s work in developing abiraterone.
Professor de Bono has been involved in the development of many novel agents, many of which are now approved drugs, functioning as chief investigator on Phase I trials such as abiraterone, olaparib and afatinib. He has served as chief investigator of multiple drugs that have changed the standard of care for prostate cancer patients including abiraterone, cabazitaxel and enzalutamide and has published more than 300 manuscripts including multiple publications in the New England Journal of Medicine and The Lancet. He has led on the study of circulating tumour cells, whole blood expression profiling and plasma DNA in metastatic prostate cancer patients and pioneered the concept of patient molecular stratification in early clinical trials in the Pharmacological Audit Trail.
Duncan Jodrell is a Senior Group Leader at the Cancer Research UK Cambridge Institute. In addition, he is the Cambridge Experimental Cancer Medicine Centre (ECMC) Lead for Early Phase Trials, the Director of the Cambridge Cancer Trials Centre and an honorary consultant at Addenbrookes Hospital. A fully trained and accredited Medical Oncologist, he completed his doctoral thesis at the Institute of Cancer Research, post-doctoral research at the University of Maryland and clinical training at the Royal Marsden Hospital and Beatson Oncology Centre. Previously a faculty member at the University of Edinburgh (where he established a research team undertaking early phase clinical trials and a pharmacology laboratory), he was elected to the Chair of Cancer Therapeutics in Cambridge in 2008. He manages a clinical research team, facilitating patients, across the East of England region, to access new therapies for cancer. The clinical team aims to facilitate the translational of CRUK and Cambridge science discoveries, into the clinic. As a Senior Group Leader in the Cancer Research UK Cambridge Institute, Duncan also undertakes laboratory research into new therapies, focusing on pancreatic cancer.
Corey J. Langer, MD, FACP is Professor of Medicine in the Hematology/Oncology Division at the University of Pennsylvania Perelman School of Medicine in Philadelphia, Pennsylvania, where he serves as Director of Thoracic Oncology in the Abramson Cancer Center. Dr Langer received his medical degree from Boston University in Boston, Massachusetts in 1981 and completed his internship and residency in medicine at the Graduate Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania. Additional postgraduate training included a fellowship in hematology/oncology at the Penn Presbyterian Medical Center and a fellowship in oncology at AOH/Fox Chase Cancer Center (FCCC). He is board certified in internal medicine and in hematology/oncology.
Dr Langer served in the oncology division of Fox Chase Cancer Center [FCCC] for 22 years from 1986 until 2008, and for the last 14 years of his tenure at FCCC, he led its Thoracic Oncology Program. He also served as the research chair of Oncology Physicians Network, a consortium of academic and community facilities in the Delaware Valley allied with FCCC. In June of 2008, he moved to the University of Pennsylvania where he currently leads the Interdisciplinary Thoracic Oncology Program (I-TOP).
Dr Langer is a fellow of the American College of Physicians and is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the International Association for the Study of Lung Cancer (IASLC), and the Society of Head and Neck Surgeons. He has served as Vice-Chair of the Radiation Therapy Oncology Group (RTOG, now NRG) and chairs its Medical Oncology Subcommittee. He also serves on the core Thoracic and Head and Neck Committees of both the Eastern Cooperative Oncology Group (ECOG) and RTOG (NRG).
Dr Langer has contributed numerous articles (>200) and abstracts (>250) to the medical literature. His work on head and neck squamous cell cancer and non-small cell lung cancer has appeared in the New England Journal of Medicine, Seminars in Oncology, Clinical Cancer Research, Journal of Clinical Oncology, Journal of Thoracic Oncology, Clinical Lung Cancer, Cancer, Lung Cancer, Cancer Investigation, and EJC. His work has also been presented at the national meetings of ASCO, AACR, ASH, SIOG and the IASLC. He has served three separate terms as a member of the editorial board of the Journal of Clinical Oncology, and is currently on the editorial boards of Clinical Lung Cancer and Clinical Advances in Hematology and Oncology. Dr Langer was also a member of PDQ editorial board/National Cancer Institute protocol submissions and while at FCCC, he served on the NCCN NSCLC and SCLC committees. He reviews articles for the New England Journal of Medicine, Journal of Clinical Oncology, Clinical Lung Cancer, Clinical Cancer Research, Cancer, Annals of Oncology, Lung Cancer, and the Journal of Thoracic Oncology. He is also a frequent lecturer at numerous medical symposia and grand rounds and serves as advisor/commentator for Projects in Knowledge, Impact, CCO and Medscape.
Finally, he is the Immediate Past President of Delaware Valley Poets, which holds monthly workshops in Mercer County, NJ and monthly readings at the Princeton Public Library. He and his wife Mindy, a retired pediatrician, live in Princeton Jcn, NJ. His daughter Adina is a historian, who previously worked for the World Trade Center Memorial Foundation in NYC and is now an Adjunct Professor in History at Georgia State; she and her husband Matt are the proud parents of Corey’s grandson, Leo Gabriel DeAngelis. Corey’s son Micah is a classical saxophonist with a degree from McGill University in Montreal, where he currently resides.
Ursula A. Matulonis, MD is Medical Director and Program Leader of the Medical Gynecologic Oncology Program at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. Her research focuses on targeted therapies for gynecologic malignancies, with a specific interest in the genetic changes in ovarian cancer and how that can lead to rationale targeted drug selection. Dr. Matulonis is the Principal Investigator of several clinical trials and translational studies for ovarian cancer. Dr. Matulonis is a Co-PI on an ovarian cancer SPORE project entitled “Identification of Oncogenic Mutations in Ovarian Cancer,” and a Co-PI on the project “Genetic relationships between breast and ovarian cancer” that is funded by the Breast Cancer Research Foundation. She is also a past recipient of a DF/HCC Ovarian Cancer SPORE Developmental Grant entitled “Genetic Fingerprinting of Ovarian Cancer.”
Dr. Matulonis serves on the National Comprehensive Cancer Network Ovarian Cancer Recommendation and Guideline Committee for both ovarian cancer and for the treatment of anemia, the Gynecologic Oncology Group Quality of Life Committee, a member of The Cancer Genome Atlas Project (TCGA) Endometrial Analysis Working Group, and is Medical Director and Board Member for the non-profit organization Ovations for the Cure. She is a recipient of the Dennis Thompson Compassionate Care Scholar award, the Lee Nadler “Extra Mile” Award, and was named one of Boston’s Best Physicians in Medical Oncology by Boston Magazine numerous times. She serves on the editorial board of the Journal of Clinical Oncology.
After receiving her MD from Albany Medical College, she completed an internship and residency at the University of Pittsburgh, followed by a medical oncology fellowship at Dana-Farber.
Dr. Mayer is Faculty Vice President for Academic Affairs at the Dana-Farber Cancer Institute, Senior Physician at the Brigham and Women’s Hospital, and the Stephen B. Kay Professor of Medicine at the Harvard Medical School where he is also Faculty Associate Dean for Admissions. He directed the Institute’s Medical Oncology Fellowship Program for 36 years, overseeing the training of several hundred oncologists. Dr. Mayer’s research interests focus on gastrointestinal cancer, a subject about which he has published extensively. Dr. Mayer established the Center for Gastrointestinal Oncology at the Dana-Farber Cancer Institute and is the past Chair of the Gastrointestinal Cancer Committee of the Cancer and Leukemia Group B, a cooperative group sponsored by the National Cancer Institute. He has served as an Associate Editor for the New England Journal of Medicine and the Journal of Clinical Oncology, is a past President of the American Society of Clinical Oncology, and is a former member of the Executive Committee of the American Board of Internal Medicine. Dr. Mayer is a graduate of Williams College and the Harvard Medical School.